TransMedics Group (NASDAQ:TMDX) Insider Anil Ranganath Sells 864 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil Ranganath sold 864 shares of TransMedics Group stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $120,199.68. Following the completion of the sale, the insider owned 13,091 shares of the company’s stock, valued at $1,821,219.92. This trade represents a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

TransMedics Group Stock Performance

TMDX stock traded down $9.22 during midday trading on Thursday, hitting $138.44. 290,500 shares of the company traded hands, compared to its average volume of 802,945. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The business has a 50 day simple moving average of $134.97 and a 200-day simple moving average of $126.78. The stock has a market capitalization of $4.75 billion, a price-to-earnings ratio of 28.25 and a beta of 1.98. TransMedics Group, Inc. has a twelve month low of $62.07 and a twelve month high of $156.00.

Analysts Set New Price Targets

Several research firms have recently weighed in on TMDX. Oppenheimer raised their price objective on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Needham & Company LLC boosted their price objective on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. raised their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $150.67.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after acquiring an additional 206 shares during the period. Salomon & Ludwin LLC purchased a new position in shares of TransMedics Group in the 3rd quarter worth $28,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group in the third quarter valued at $29,000. Optiver Holding B.V. lifted its stake in shares of TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after purchasing an additional 191 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.